It is being tested in a phase 1 trial for the safety, tolerability, pharmacokinetics, and pharmacodynamics of BCX9250 in patients with FOP; (vi) Palovarotene: Palovarotene is another small molecule that activates retinoic acid receptor gamma (RARγ), which inhibits activin A expression and signaling. This evidence concerns the gene RARG and fibrodysplasia ossificans progressiva.